| Date | Title | Description |
| 11.04.2018 | Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout | Biotech buyouts are all the rage these days. Today, it’s Alexion’s $ALXN turn to score with a deal that adds a Phase III drug for a rare disease to its pipeline — marking the new executive crew’s “first step” in reorganizing the... |
| 18.05.2016 | Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled | Wilson Therapeutics AB (publ), announces that the company's ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled.
Rea... |
| 17.04.2014 | Wilson Therapeutics Receives $40M in Series B Funding | Wilson Therapeutics, a Stockholm, Sweden-based biopharmaceutical company, received $40m in Series B funding.
The round was co-led by Abingworth LLP and MVM Life Science Partners, with participation from founding investor HealthCap. In conju... |
| 16.04.2014 | Wilson Therapeutics Secures $40M |
STOCKHOLM, SWEDEN, Biopharmaceutical company, today announced that it has closed a $40 million Series B financing.
>> Click here for more funding data on Wilson Therapeutics
>> To export Wilson Therapeutics funding data to P... |
| - | Wilson Therapeutics AB (PUBL) Interim Report January 1 – March 31, 2016 | Significant events during the period
Significant events after the end of the period
”On May 12 Wilson Therapeutics was listed on Nasdaq Stockholm. This was evidently an important strategic milestone for us. I would like to use this opport... |
| - | Wilson Therapeutics AB (Publ) Year-End Report 2017 | Feb 21, 2018
“After a highly successful year, we are excited that we now have entered the pivotal phase of development for WTX101. Backed by positive Phase 2 data, an experienced international team and a solid balance sheet, we are very we... |
| - | Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease | Wilson Therapeutics AB (publ), announced today that the Phase 2 study of WTX101 (bis-choline tetrathiomolybdate; Decuprate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patien... |
| - | Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion | HealthCap founded Wilson in June 2012 following a proactive sourcing of assets in the orphan disease space and has contributed in developing the company and its lead product, WTX101, into Phase 3 clinical studies for novel treatment of Wils... |
| - | Promising preliminary long-term data from WTX101 Phase 2 extension study to be presented at AASLD Annual Meeting | Oct 01, 2017
Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding ag... |
| - | Wilson Therapeutics’ Nomination Committee appointed | In accordance with the decision of the Annual General Meeting on 17 May 2017, Wilson Therapeutics’ Nomination Committee for the AGM 2018 shall comprise the Chairman of the Board and one representative for each of the three largest sharehold... |
| - | Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting | Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class... |
| - | WTX101 granted Fast Track designation by the U.S. FDA for the treatment of Wilson Disease | Dec 14, 2017
Wilson Therapeutics AB (publ), today announced that the U.S. Food and Drug Administration (FDA) has granted WTX101 Fast Track designation for the treatment of Wilson Disease. The FDA’s Fast Track program is designed to facilit... |
| - | Final Phase 2 results for WTX101 accepted as a late-breaker presentation at EASL Annual Meeting | Apr 05, 2017
Wilson Therapeutics AB (publ), announced today that the final data from the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper modulating agent in development for patie... |
| - | WILSON THERAPEUTICS ANNOUNCES START OF PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF WTX101 IN NEWLY DIAGNOSED WILSON DISEASE PATIENTS | STOCKHOLM, November 17, 2014 (PR NEWSWIRE) – Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced the start of a Phase 2 clinical study to evaluate efficacy and safety of its lead product candidate WTX101 i... |
| - | First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease | Wilson Therapeutics (publ) today announced that the first patient has been enrolled in the pivotal Phase 3 FOCuS clinical trial evaluating WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding age... |
| - | WILSON THERAPEUTICS ANNOUNCES SUPPORT OF THE BIG WOW TO RAISE AWARENESS OF WILSON’S DISEASE | STOCKHOLM, June 17, 2015 (PR NEWSWIRE) – Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced its sponsorship of the first annual Big Walk on Wilson’s (BIG WOW). The event will take place on September 19, 2015... |
| - | WILSON THERAPEUTICS ANNOUNCES PRESENTATION OF WTX101-201 PHASE 2 STUDY AT THE EASL 50TH INTERNATIONAL LIVER CONGRESS 2015 | STOCKHOLM, April 16, 2015 (PR NEWSWIRE) – Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company’s ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming ... |
| - | SAVE THE DATE: Wilson Therapeutics to Host Capital Markets Day in Stockholm on 21 March 2018 | Wilson Therapeutics (publ) will host a Capital Markets Day in Stockholm on Wednesday, 21 March 2018 for investors, analysts and media. Members of the senior management team will be joined by Frederick K. Askari MD, PhD, Associate Professor ... |
| - | Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting | Wilson Therapeutics AB (publ), announced today a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver, BC, 4-8 June, 2017. The presentation highlighted results from the recently comple... |
| - | HealthCap’s 35th IPO as HealthCap VI company Wilson Therapeutics completes listing on Nasdaq OMX Stockholm | Wilson Therapeutics AB a rare disease focused biopharmaceutical company has successfully completed its Initial Public Offering on Nasdaq OMX Stockholm’s main market. Trading started today under the ticker WTX.
www.wilsontherapeutics.com/en... |
| - | WILSON THERAPEUTICS APPOINTS VINCENT METZLER AS VICE PRESIDENT COMMERCIAL PLANNING & LAUNCH STRATEGY | Wilson Therapeutics AB (publ), announces the appointment of Vincent Metzler as Vice President Commercial Planning & Launch Strategy. Dr Metzler will report to CEO Jonas Hansson and will join the company’s management team.
Dr Metzler is... |
| - | Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting | Apr 25, 2017
WTX101-201 was a 24-week open-label Phase 2 study evaluating the efficacy and safety of WTX101 monotherapy in 28 newly-diagnosed adult patients with Wilson Disease, who had received either no prior treatment for Wilson Disease... |
| - | Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting | Wilson Therapeutics AB (publ), announced today that the final data from the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper modulating agent with a unique mode of action for the t... |
| - | Wilson Therapeutics announces agenda for Capital Markets Day on 21 March 2018 | Mar 12, 2018
Wilson Therapeutics (publ) is pleased to announce the agenda for its Capital Markets Day to be held in Stockholm on Wednesday 21 March 2018.
Members of the senior management team will be joined by Dr. Frederick K. Askari MD, ... |
| - | Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS | Jun 09, 2017
ALS is a neurodegenerative disease, in which the nerve cells controlling the body’s muscles gradually degenerate, leading to general paralysis and respiratory failure. Median survival for an ALS patient is three to five years.... |
| - | WILSON THERAPEUTICS AB (PUBL) INTERIM REPORT JANUARY 1 – JUNE 30, 2016 | ”Data from our ongoing phase II trial continue to indicate that Decuprate® has the potential to address the unmet medical needs in Wilson Disease. Although the results are promising it is important to underline that these results are prelim... |
| - | WILSON THERAPEUTICS ANNOUNCES INITIAL PUBLIC OFFERING ON NASDAQ STOCKHOLM | Apr 29, 2016
https://www.wilsontherapeutics.com/ipo
Jonas Hansson, CEO
Tel: +46 (0)70 944 18 77
Email: *protected email*
Anders Martin-Löf, CFO
Tel: +46 (0)70 683 79 77
Email: *protected email*
Wilson Therapeutics is a biopharmace... |
| - | Wilson Therapeutics secures $40 million private financing to advance late stage development program for Wilson disease | STOCKHOLM, April 16, 2014 (PR NEWSWIRE) – Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP (“MVM”... |
| - | Wilson Therapeutics AB (publ) Interim Report January 1 – September 30, 2016 | Clinical trial on track, final results expected before year-end.
”Preliminary data from our ongoing phase 2 trial continue to indicate that WTX101 has the potential to address the unmet medical needs in Wilson Disease, and we are set to re... |
| - | Promising preliminary long-term data for WTX101 in Wilson Disease highlighted at The Liver Meeting® | Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding agent for the ... |
| - | Wilson Therapeutics to host conference call to provide fourth quarter 2017 business update | Feb 14, 2018
On February 21, 2018, at 07:00 CET, Wilson Therapeutics will publish its year-end report for 2017. All interested parties are invited to participate in a web-cast telephone conference at 10:00 CET, on the same day. The event w... |
| - | Wilson Therapeutics’ 2017 Annual Report published | Apr 27, 2018
As of today, the 2017 Annual Report of Wilson Therapeutics AB (publ) is available as a pdf file on the company’s website www.wilsontherapeutics.com.
Printed copies can be ordered by post to Wilson Therapeutics AB (publ), Kung... |
| - | Wilson Therapeutics presents updated preliminary clinical data on WTX101 at the AASLD Liver Meeting | Wilson Therapeutics AB (publ), today announced that updated preliminary data from the company’s ongoing Phase 2 clinical trial for WTX101 (bis-choline tetrathiomolybdate; Decuprate®) in Wilson Disease will be presented at the Liver Meeting®... |
| - | WILSON THERAPEUTICS ANNOUNCES SUPPORT OF THE ANNUAL EVENT BIG WOW TO RAISE AWARENESS OF WILSON DISEASE | “As the father of three sons, all diagnosed with Wilson Disease, I have personal experience with the importance of an early diagnosis,” said Christopher Simopoulos, MD, one of the initiators of the Big Wow.
“We started the Big Wow last yea... |
| - | Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled | Wilson Therapeutics AB (publ), announces that the company’s ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled.
WTX10... |
| - | Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017 | July 1 – September 30, 2017
January 1 – September 30, 2017
Significant events during the period January 1 – September 30, 2017
Significant events after the end of the reporting period
”We are excited to move WTX101 into the pivotal phas... |
| - | Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease | Wilson Therapeutics (publ) today announced that the discussions with the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA), regarding the study protocol for the single pivotal Phase 3 FOCuS trial for WTX101 in W... |
| - | Wilson Therapeutics AB (publ) Interim Report January 1 – June 30, 2017 | Preparations for Phase 3 progressing
April 1 – June 30, 2017
January 1 – June 30, 2017
Significant events during the period January 1 – June 30, 2017
”During the first half of the year, we presented final data from our successful Phase ... |
| - | Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology | Wilson Therapeutics AB (publ) announces that it will present preliminary data from the ongoing extension of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding age... |
| - | Wilson Theraputics AB (publ) Year-end Report 2016 | Feb 23, 2017
October 1 – December 31, 2016
January 1 – December 31, 2016
Significant events during 2016
Significant events after the end of the report period
“We ended 2016 with great news, reporting the successful completion of our Ph... |
| - | WILSON THERAPEUTICS APPOINTS ANDREW KAY AS CHAIRMAN | STOCKHOLM, October 20, 2015 (PR NEWSWIRE) – Wilson Therapeutics AB, a privately held biopharmaceutical company, today announced that Andrew Kay has been appointed as Chairman of its Board of Directors. The company’s previous Chairman, Hugh ... |
| - | Wilson Therapeutics AB (publ) Interim Report January 1 – March 31, 2017 | May 17, 2017
Extraordinary general meeting was held in January 2017 and resolved to implement a long term incentive program
”During the first part of the year we have been engaged in analyzing and presenting the data from our Phase 2 tria... |
| - | Wilson Therapeutics to host conference call to provide first quarter 2017 business update | May 10, 2017
On May 17, 2017, at 08:00 CET, Wilson Therapeutics will publish its interim report for the first quarter 2017. All interested parties are invited to participate in a web-cast telephone conference, which will include a presenta... |
| - | WILSON THERAPEUTICS PRESENTS DATA ON DECUPRATE™ (WTX101) FROM ONGOING PHASE 2 STUDY AT THE INTERNATIONAL LIVER CONGRESS™ 2016 | Wilson Therapeutics AB, announces that data from the company’s ongoing Phase 2 clinical trial for Decuprate™ (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease will be presented today at The International Liver Congress™ 2016, takin... |
| - | WILSON THERAPEUTICS HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 244 MILLION | Dec 08, 2017
Read the press release
“Wilson Therapeutics has completed a directed share issue of approximately SEK 244 million“.
Source: Wilson Therapeutics |
| - | Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting | Apr 12, 2018
Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational ... |
| - | Wilson Therapeutics presents encouraging clinical data on Decuprate® at the Congress of the European Academy of Neurology | Wilson Therapeutics AB (publ), announces that preliminary data from the company’s ongoing Phase II clinical trial for Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease were presented at the 2ndCongress of the European Ac... |
| - | Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn Odlander | The Annual General Meeting of Wilson Therapeutics AB (publ), has elected Dr. Birgitte Volck and Dr. Björn Odlander as new members of the Board of Directors.
Dr. Birgitte Volck is Senior Vice President, Head of R&D Rare Disease at Glaxo... |
| - | Wilson Therapeutics Appoints Anders Martin-Löf as Chief Financial Officer | STOCKHOLM, November 2, 2015 (PR NEWSWIRE) – Wilson Therapeutics AB, a privatelyheld
biopharmaceutical company, today announced the appointment of Anders Martin-Löf as
Chief Financial Officer (CFO). Mr. Martin-Löf will report to CEO Jonas ... |
